Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 1
2007 1
2008 1
2009 1
2011 5
2012 2
2013 3
2014 5
2015 7
2016 9
2017 3
2018 6
2019 8
2020 4
2021 5
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Norovirus vaccine: one step closer.
Vesikari T, Blazevic V. Vesikari T, et al. Among authors: blazevic v. J Infect Dis. 2015 Mar 15;211(6):853-5. doi: 10.1093/infdis/jiu498. Epub 2014 Sep 9. J Infect Dis. 2015. PMID: 25210142 No abstract available.
Modular vaccine platform based on the norovirus-like particle.
Lampinen V, Heinimäki S, Laitinen OH, Pesu M, Hankaniemi MM, Blazevic V, Hytönen VP. Lampinen V, et al. Among authors: blazevic v. J Nanobiotechnology. 2021 Jan 19;19(1):25. doi: 10.1186/s12951-021-00772-0. J Nanobiotechnology. 2021. PMID: 33468139 Free PMC article.
Development and maturation of norovirus antibodies in childhood.
Blazevic V, Malm M, Honkanen H, Knip M, Hyöty H, Vesikari T. Blazevic V, et al. Microbes Infect. 2016 Apr;18(4):263-9. doi: 10.1016/j.micinf.2015.12.004. Epub 2015 Dec 25. Microbes Infect. 2016. PMID: 26724451 Free article.
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
Leroux-Roels I, Maes C, Joye J, Jacobs B, Jarczowski F, Diessner A, Janssens Y, Waerlop G, Tamminen K, Heinimäki S, Blazevic V, Leroux-Roels G, Klimyuk V, Adachi H, Hiruta K, Thieme F. Leroux-Roels I, et al. Among authors: blazevic v. Front Immunol. 2022 Oct 7;13:1021500. doi: 10.3389/fimmu.2022.1021500. eCollection 2022. Front Immunol. 2022. PMID: 36275772 Free PMC article. Clinical Trial.
60 results